Medical solutions

Prescription

The Prescription Business Unit is one of the three business units within Galderma.

Our mission

When patients visit healthcare professionals, and dermatologists in particular, they seek relief from skin diseases that have physical, as well as psychological or social consequences on their daily lives.

Our aim is to provide these dermatologists and healthcare professionals with the solutions their patients need to find relief from the burden of these diseases.

Our prescription medicines

To view our prescription brands, visit the brand section.

Innovation

Today, our innovation is focused on developing new solutions in disease areas with unmet medical needs, such as atopic dermatitis, dermato-oncology and acne. We do this by partnering with companies and institutions throughout the world, to combine our expertise and build on it so that, together, we can find innovative ways to treat the disease and improve patients’ quality of life.

 

Our policy on Expanded Access Program

At this time, Galderma does not have an expanded access program that allows patients to have access to the company’s investigational therapies outside of clinical trials or prior to FDA approval. Galderma believes clinical trials are the most appropriate way for patients to access investigational medicines developed by Galderma. In these trials, the safety and efficacy of investigational medicines are rigorously assessed by Galderma and the relevant regulatory agencies in order to understand the medicine’s benefits, risks, and appropriate use, including whether or not it should be approved as a therapy for its intended use. Obtaining regulatory approval is the best way to bring safe and effective medicines to the greatest number of patients who may benefit from treatment.

Galderma may update this policy as drug development programs are progressing and reassess the approach to expanded access programs. Should patients, families, or physicians have any questions, please contact our Medical Information department by email at [email protected]